Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 16Completed 10Recruiting 8Unknown 7Terminated 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1Advanced Solid Tumours 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × ceralasertib × Clear all
NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

OHSU Knight Cancer Institute

Phase 2 Terminated
24 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT06929260 2026-01-22

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

AstraZeneca

Phase 1 Terminated
1 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated
67 enrolled 10 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡